131 related articles for article (PubMed ID: 7654494)
1. The plasma concentrations of isosorbide 5-mononitrate (5-ISMN) administered in an extended-release form to patients with acute myocardial infarction.
McClennen W; Hornestam B; Jonsson UE; Held P
Br J Clin Pharmacol; 1995 Jun; 39(6):704-8. PubMed ID: 7654494
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics of isosorbide-5-mononitrate after oral administration of an extended-release mononitrate formulation versus a standard dinitrate formulation.
Kosoglou T; Patrick JE; Cohen A; Radwanski E; Christopher D; Affrime MB
Clin Ther; 1995; 17(2):241-51. PubMed ID: 7614524
[TBL] [Abstract][Full Text] [Related]
3. Plasma profile and haemodynamic tolerance to isosorbide-5-mononitrate in controlled-release form.
Jähnchen E
Br J Clin Pharmacol; 1992; 34 Suppl 1(Suppl 1):15S-17S. PubMed ID: 1633073
[TBL] [Abstract][Full Text] [Related]
4. [Determination of isosorbide-5-mononitrate in plasma by GC-ECD and study on its pharmacokinetics in ten volunteers].
Yang LL; Yuan YS; Zhao FL
Yao Xue Xue Bao; 1997 Oct; 32(10):773-6. PubMed ID: 11596222
[TBL] [Abstract][Full Text] [Related]
5. Sex-related differences in the pharmacokinetics of isosorbide-5-mononitrate (60 mg) after repeated oral administration of two different original prolonged release formulations.
Vree TB; Dammers E; Valducci R
Int J Clin Pharmacol Ther; 2004 Aug; 42(8):463-72. PubMed ID: 15366327
[TBL] [Abstract][Full Text] [Related]
6. Twenty-four hour plasma profile of sustained-release isosorbide mononitrate in healthy volunteers and in patients with chronic stable angina. Two open label trials.
Baxter T; Eadie CJ
Br J Clin Pharmacol; 1997 Mar; 43(3):333-5. PubMed ID: 9088592
[TBL] [Abstract][Full Text] [Related]
7. Isosorbide mononitrate 30% immediate-release 70% sustained-release formulation: a review. DUMQOL (DUtch Mononitrate Quality of Life) Study Group.
Cleophas TJ; Niemeyer MG; Zwinderman AH; van der Wall EE
Angiology; 2000 Aug; 51(8):631-8. PubMed ID: 10959515
[TBL] [Abstract][Full Text] [Related]
8. Comparison of the time to onset of action on myocardial ischaemia following intravenous administration of isosorbide dinitrate and 5-isosorbide mononitrate in Chinese patients.
Wu ZG; Li JN; Fan M; Shang YK; Zhang YW; Bai J; Ding R; Cheng JM; Liang C
Arzneimittelforschung; 2004; 54(5):275-9. PubMed ID: 15212189
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics of three organic nitrates in Chinese healthy male volunteers.
Chen J; Jiang XG; Cai L; Lu W; Gao KP; Shi ZQ; Zhang QZ
Arzneimittelforschung; 2004; 54(4):203-6. PubMed ID: 15146932
[TBL] [Abstract][Full Text] [Related]
10. Absorption of isosorbide-5-mononitrate at specific sites in the gastrointestinal tract.
Kramer WG
J Clin Pharmacol; 1994 Dec; 34(12):1218-21. PubMed ID: 7738218
[TBL] [Abstract][Full Text] [Related]
11. [Assay of plasma isosorbide dinitrate and its metabolites after oral administration of immediate and delayed-action forms].
Audry E; Dallet P; Dubost JP; Langlois MH; Ernouf D; Narcisse G
Ann Pharm Fr; 1989; 47(4):235-41. PubMed ID: 2637644
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of controlled-release isosorbide-5-mononitrate in Japanese patients with stable effort angina pectoris.
Shimada K; Sunayama S; Nakazato K; Satoh H; Kusama Y; Kawakubo K; Daida H
Int Heart J; 2006 Sep; 47(5):695-705. PubMed ID: 17106140
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetic profile of a new controlled-release isosorbide-5-mononitrate 60 mg scored tablet (Monoket Multitab).
Stockis A; De Bruyn S; Deroubaix X; Jeanbaptiste B; Lebacq E; Nollevaux F; Poli G; Acerbi D
Eur J Pharm Biopharm; 2002 Jan; 53(1):49-56. PubMed ID: 11777752
[TBL] [Abstract][Full Text] [Related]
14. Randomized controlled trial of oral captopril, of oral isosorbide mononitrate and of intravenous magnesium sulphate started early in acute myocardial infarction: safety and haemodynamic effects. ISIS-4 (Fourth International Study of Infarct Survival) Pilot Study Investigators.
Flather M; Pipilis A; Collins R; Budaj A; Hargreaves A; Kolettis T; Jacob A; Millane T; Fitzgerald L; Cedro K
Eur Heart J; 1994 May; 15(5):608-19. PubMed ID: 8055999
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetic interaction of the direct renin inhibitor aliskiren with furosemide and extended-release isosorbide-5-mononitrate in healthy subjects.
Vaidyanathan S; Bartlett M; Dieterich HA; Yeh CM; Antunes A; Howard D; Dole WP
Cardiovasc Ther; 2008; 26(4):238-46. PubMed ID: 19035874
[TBL] [Abstract][Full Text] [Related]
16. Development of monolithic osmotic pump tablet system for isosorbide-5-mononitrate delivery and evaluation of it in vitro and in vivo.
Duan X; Liu Q; Zhang Y; Bi K; Chen X; Wang Y; Luo G
Drug Dev Ind Pharm; 2009 Apr; 35(4):499-507. PubMed ID: 18979308
[TBL] [Abstract][Full Text] [Related]
17. ISIS-4: a randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58,050 patients with suspected acute myocardial infarction. ISIS-4 (Fourth International Study of Infarct Survival) Collaborative Group.
Lancet; 1995 Mar; 345(8951):669-85. PubMed ID: 7661937
[TBL] [Abstract][Full Text] [Related]
18. Bioavailability of isosorbide dinitrate and its two mononitrate metabolites from sustained-release formulations.
Chasseaud LF; Doyle E; Taylor T; Darragh A; Lambe RF
Int J Clin Pharmacol Ther Toxicol; 1983 Oct; 21(10):514-8. PubMed ID: 6642789
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetic properties of isosorbide-5-mononitrate under fasting and fed conditions in healthy male subjects.
Jin C; Jeon JY; Im YJ; Jeong JA; Kim Y; Chae SW; Bentz J; Kumke T; Kim MG
Int J Clin Pharmacol Ther; 2015 Jan; 53(1):97-106. PubMed ID: 25492848
[TBL] [Abstract][Full Text] [Related]
20. Preserved endothelial function after long-term eccentric isosorbide mononitrate despite moderate nitrate tolerance.
Müller S; Laber U; Müllenheim J; Meyer W; Kojda G
J Am Coll Cardiol; 2003 Jun; 41(11):1994-2000. PubMed ID: 12798571
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
